| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | LALP1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human ENTPD7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ENTPD7抗体的模拟参考文献示例(仅供格式参考，具体文献需通过学术数据库查询)：
---
1. **文献名称**: *"Characterization of ENTPD7 as a novel ectonucleotidase in hepatocellular carcinoma"*
**作者**: Zhang L, et al.
**摘要**: 研究报道了ENTPD7在肝癌细胞中的高表达，开发了特异性抗体用于检测其蛋白水平。实验表明，ENTTPD7通过水解胞外ATP调控肿瘤微环境，促进癌细胞侵袭。
---
2. **文献名称**: *"Development of a monoclonal antibody against human ENTPD7 for immunohistochemical analysis"*
**作者**: Tanaka K, et al.
**摘要**: 研究团队成功制备了针对ENTPD7的单克隆抗体，验证了其在组织切片中的特异性染色能力，并发现ENTPD7在结肠癌组织中表达上调，可能与肿瘤代谢异常相关。
---
3. **文献名称**: *"ENTPD7 regulates intestinal inflammation via purinergic signaling pathways"*
**作者**: Smith J, et al.
**摘要**: 通过使用ENTPD7抗体进行蛋白定位，研究发现该酶在肠道上皮细胞中通过降解胞外核苷酸抑制炎症反应，提示其作为炎症性肠病潜在治疗靶点。
---
4. **文献名称**: *"Structural and functional insights into ENTPD7 using CRISPR/Cas9 and antibody-based approaches"*
**作者**: Wang Y, et al.
**摘要**: 结合基因编辑技术和ENTPD7抗体，揭示了ENTPD7的酶活性结构域及其在细胞迁移中的调控作用，为靶向干预提供了分子基础。
---
**注意**：以上文献为示例性内容，实际文献需通过PubMed、Google Scholar等平台检索关键词(如“ENTPD7 antibody”“ENTPD7 function”)获取。
**Background of ENTPD7 Antibody**
The ENTPD7 (Ectonucleoside Triphosphate Diphosphohydrolase 7) antibody is a tool used to study the ENTPD7 enzyme, a member of the ectonucleoside triphosphate diphosphohydrolase family. ENTPD7 hydrolyzes extracellular nucleotides like ATP and ADP, regulating purinergic signaling pathways mediated by P2 receptors. This enzyme is implicated in modulating cellular processes such as proliferation, inflammation, and immune responses.
ENTPD7 is structurally characterized by its transmembrane domains and extracellular catalytic site, distinguishing it from other ENTPD family members (e.g., CD39/ENTPD1). It is expressed in specific tissues, including the gastrointestinal tract, liver, and certain cancers, suggesting roles in tissue homeostasis and disease.
The ENTPD7 antibody is widely utilized in research to detect protein expression via techniques like Western blotting, immunohistochemistry, or flow cytometry. It aids in exploring ENTPD7's functional roles, such as its contribution to nucleotide metabolism in tumor microenvironments or its interaction with immune cells. Studies also investigate its potential as a therapeutic target, particularly in cancers where dysregulated purinergic signaling promotes progression.
Commercial ENTPD7 antibodies are typically developed in hosts like rabbits or mice, targeting specific epitopes (e.g., N-terminal regions). Validation includes reactivity checks across species and applications. Research using these antibodies continues to uncover ENTPD7's pathophysiological relevance, bridging gaps in understanding extracellular nucleotide dynamics and their therapeutic modulation.
×
